BiomX Inc.

BiomX Inc. (PHGE) is a clinical-stage biopharmaceutical company developing phage-based therapies to treat drug-resistant bacterial infections, with programs targeting conditions including atopic dermatitis and chronic rhinosinusitis. The company entered public markets in 2019 through a business combination with Chardan Healthcare Acquisitions Corp., a blank-check vehicle sponsored by Chardan Capital Markets. BiomX filed a Form S-1 registration statement with the SEC on June 29, 2026, representing the company's most recent securities filing on record. BiomX operates in the clinical-stage biotechnology and infectious disease sector. Sign up on SpacDesk for full filing history, deal data, and real-time alerts across the SPAC universe.